The burden of AIP mutations in pituitary adenoma patients from the UK

Authors:
  • FCF Caimari
    F Caimari
  • MDM N Dang
    M N Dang
  • PGP Gabrovska
    P Gabrovska
  • LHL C Hernandez-Ramirez
    L C Hernandez-Ramirez
  • KSK Stals
    K Stals
  • ABA M Bussell
    A M Bussell
  • TCT Cranston
    T Cranston
  • NKN Karavitaki
    N Karavitaki
  • AKA V Kumar
    A V Kumar
  • SHS Hunter
    S Hunter
  • TKT Kearney
    T Kearney

Abstract
Introduction: Familial isolated pituitary adenoma (FIPA) and young-onset sporadic pituitary adenoma patients are suggested to be screened for mutations in AIP, a gene described in 2006 and amenable to UK testing since 2008. Methods: affected subjects have been tested in Exeter and Oxford genetic laboratories. Data were collected from 120 FIPA-families and 193 sporadic cases with young-onset disease (2 were used for statistical analysis. Results: We have identified 38 AIP pos kindreds (16 families and 22 simplex kindreds), representing 77 affected patients. In the 16 families (13.3% of FIPA-families), out of 211 members tested, 121 were carriers and 55 were affected. Of the 193 young simplex patients (44.5% GH-excess), 22 (11.4%) were AIPpos and 17 unaffected carrier family members were identified. 96 (60%) AIPpos carriers had a founder mutation: p.R304*, 79 subjects and p.F269_H275dup, 17 subjects. In the AIPpos FIPA kindreds, those affected were more frequently males (60.7 vs 41.1%, PPP=0.034) compared to AIPneg FIPA families. There were no differences in tumour size (77.6 vs 72.8% macroadenomas) or extrasellar extension (40 vs 39.8%). Of young sporadic cases, AIPpos patients were more frequently males (81.8 vs 46.8%, P=0.003), with larger adenomas (100% vs 80.3% macroadenomas, P=0.043) and extrasellar extension (100 vs 50%, P=0.004), but no differences in age-of-onset (18(13.5–23) vs 20 (15–25)) or pituitary apoplexy. GH&GH/PRL-secreting adenomas were more frequent in AIPpos compared to AIPneg cases (FIPA: 76.8 vs 31%, PPAIP mutations are found in 13.3% of families and 11.4% of young-onset patients. The two founder mutations identified are responsible for over half of the affected and unaffected carrier cases.